Similarly, in small‐cell lung cancer, Bcl‐xl upregulation contributes to resistance against etoposide and other standard chemotherapeutics, suggesting a potential benefit in targeting Bcl‐xl to sensitize tumor cells to treatment.1 This evidence concerns the gene BCL2L1 and neoplasm.